Puma Biotechnology Stock Current Liabilities
| PBYI Stock | USD 3.14 0.12 3.97% |
Puma Biotechnology fundamentals help investors to digest information that contributes to Puma Biotechnology's financial success or failures. It also enables traders to predict the movement of Puma Stock. The fundamental analysis module provides a way to measure Puma Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Puma Biotechnology stock.
The current Total Current Liabilities is estimated to decrease to about 56.7 M. The current Non Current Liabilities Total is estimated to decrease to about 68.1 M. Puma | Current Liabilities |
Puma Biotechnology Company Current Liabilities Analysis
Puma Biotechnology's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Puma Biotechnology Current Liabilities | 32.44 M |
Most of Puma Biotechnology's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Puma Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Puma Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Puma Biotechnology is extremely important. It helps to project a fair market value of Puma Stock properly, considering its historical fundamentals such as Current Liabilities. Since Puma Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Puma Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Puma Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Puma Current Liabilities Historical Pattern
Today, most investors in Puma Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Puma Biotechnology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Puma Biotechnology current liabilities as a starting point in their analysis.
Puma Biotechnology Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Puma Liabilities And Stockholders Equity
Liabilities And Stockholders Equity |
|
In accordance with the recently published financial statements, Puma Biotechnology has a Current Liabilities of 32.44 M. This is 98.15% lower than that of the Biotechnology sector and 94.03% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.59% higher than that of the company.
Puma Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Puma Biotechnology's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics of similar companies.Puma Biotechnology is currently under evaluation in current liabilities category among its peers.
Puma Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Puma Biotechnology from analyzing Puma Biotechnology's financial statements. These drivers represent accounts that assess Puma Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Puma Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 339.2M | 406.1M | 123.5M | 189.0M | 204.1M | 193.9M | |
| Enterprise Value | 399.5M | 441.7M | 177.1M | 227.1M | 231.0M | 219.4M |
Puma Biotechnology ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Puma Biotechnology's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Puma Biotechnology's managers, analysts, and investors.Environmental | Governance | Social |
Puma Fundamentals
| Return On Equity | 0.42 | ||||
| Return On Asset | 0.0973 | ||||
| Profit Margin | 0.1 % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 136.91 M | ||||
| Shares Outstanding | 49.09 M | ||||
| Shares Owned By Insiders | 15.14 % | ||||
| Shares Owned By Institutions | 67.78 % | ||||
| Number Of Shares Shorted | 3.19 M | ||||
| Price To Earning | 18.52 X | ||||
| Price To Book | 2.07 X | ||||
| Price To Sales | 0.61 X | ||||
| Revenue | 235.64 M | ||||
| Gross Profit | 172.94 M | ||||
| EBITDA | 44.78 M | ||||
| Net Income | 21.59 M | ||||
| Cash And Equivalents | 77.96 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 111.49 M | ||||
| Debt To Equity | 5.19 % | ||||
| Current Ratio | 2.04 X | ||||
| Book Value Per Share | 1.45 X | ||||
| Cash Flow From Operations | 27.01 M | ||||
| Short Ratio | 14.34 X | ||||
| Earnings Per Share | 0.47 X | ||||
| Price To Earnings To Growth | 0.03 X | ||||
| Target Price | 4.33 | ||||
| Number Of Employees | 185 | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 148.24 M | ||||
| Total Asset | 230.53 M | ||||
| Retained Earnings | (1.35 B) | ||||
| Working Capital | 56.8 M | ||||
| Current Asset | 223.55 M | ||||
| Current Liabilities | 32.44 M | ||||
| Net Asset | 230.53 M |
About Puma Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Puma Biotechnology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Puma Biotechnology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Puma Biotechnology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Puma Biotechnology Stock:Check out Puma Biotechnology Piotroski F Score and Puma Biotechnology Altman Z Score analysis. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.417 | Earnings Share 0.47 | Revenue Per Share 5.045 | Quarterly Revenue Growth 0.435 | Return On Assets 0.0973 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.